

# **Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030**

<https://marketpublishers.com/r/D2A32AB30D30EN.html>

Date: February 2025

Pages: 153

Price: US\$ 5,950.00 (Single User License)

ID: D2A32AB30D30EN

## **Abstracts**

This report can be delivered to the clients within 3 Business Days

### **Dopamine Agonist Market Growth & Trends**

The global dopamine agonist market size is anticipated to reach USD 1.83 billion by 2030 and is projected to grow at a CAGR of 5.70% during the forecast period, according to a new report by Grand View Research, Inc. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson's disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug

action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth. Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies. Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care. Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson's disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders. As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

#### Dopamine Agonist Market Report Highlights

In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.

The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson's disease, restless legs syndrome (RLS), and

hyperprolactinemia.

Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.

North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

## Contents

### CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
  - 1.3.1. Information Procurement
  - 1.3.2. Information or Data Analysis
  - 1.3.3. Market Formulation & Data Visualization
  - 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
  - 1.4.1. List of Data Sources

### CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

### CHAPTER 3. DOPAMINE AGONIST MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Parent Market Outlook
- 3.2. Ancillary Market Outlook
- 3.3. Market Dynamics
  - 3.3.1. Market Drivers Analysis
    - 3.3.1.1. Rising prevalence of neurological disorders
    - 3.3.1.2. Growing geriatric population
    - 3.3.1.3. Advancements in drug formulations & delivery methods
  - 3.3.2. Market Restraints Analysis
    - 3.3.2.1. Severe side effects & safety concerns
    - 3.3.2.2. Emerging alternative therapies
- 3.4. Dopamine Agonist Analysis Tools
  - 3.4.1. Porter's Analysis
    - 3.4.1.1. Bargaining power of the suppliers
    - 3.4.1.2. Bargaining power of the buyers
    - 3.4.1.3. Threats of substitution
    - 3.4.1.4. Threats from new entrants
    - 3.4.1.5. Competitive rivalry

### 3.4.2. PESTEL Analysis

#### 3.4.2.1. Political landscape

#### 3.4.2.2. Economic and Social landscape

#### 3.4.2.3. Technological landscape

#### 3.4.2.4. Environmental landscape

#### 3.4.2.5. Legal landscape

### 3.5. Pipeline Analysis

#### 3.5.1. Phase

#### 3.5.2. Phase

#### 3.5.3. Phase

## **CHAPTER 4. DOPAMINE AGONIST MARKET: BY DRUG ESTIMATES & TREND ANALYSIS**

### 4.1. Dopamine Agonist Market: Drug Segment Dashboard

### 4.2. Dopamine Agonist Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)

### 4.3. Non-Ergot Dopamine Agonists

#### 4.3.1. Non-Ergot Dopamine Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### 4.4. Ergot Alkaloids

#### 4.4.1. Ergot Alkaloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 5. DOPAMINE AGONIST MARKET: APPLICATION ESTIMATES & TREND ANALYSIS**

### 5.1. Dopamine Agonist Market: Application Segment Dashboard

### 5.2. Dopamine Agonist Market: By Application Movement Analysis, 2024 & 2030 (USD Million)

### 5.3. Parkinson's Disease

#### 5.3.1. Parkinson's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### 5.4. Restless Legs Syndrome (RLS)

#### 5.4.1. Restless Legs Syndrome (RLS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### 5.5. Hyperprolactinemia

#### 5.5.1. Hyperprolactinemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### 5.6. Others

#### 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### **CHAPTER 6. DOPAMINE AGONIST MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS**

#### 6.1. Dopamine Agonist Market: Route of Administration Segment Dashboard

#### 6.2. Dopamine Agonist Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)

#### 6.3. Oral

##### 6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 6.4. Injectable

##### 6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 6.5. Others

##### 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### **CHAPTER 7. DOPAMINE AGONIST MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS**

#### 7.1. Dopamine Agonist Market: Distribution Channel Segment Dashboard

#### 7.2. Dopamine Agonist Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)

#### 7.3. Retail Pharmacies

##### 7.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 7.4. Hospital Pharmacies

##### 7.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 7.5. Other Pharmacies

##### 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

### **CHAPTER 8. DOPAMINE AGONIST MARKET: REGIONAL ESTIMATES & TREND ANALYSIS**

#### 8.1. Dopamine Agonist Market Share, By Region, 2024 & 2030 (USD Million)

#### 8.2. North America

##### 8.2.1. North America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 8.2.2. U.S.

8.2.2.1. Key Country Dynamics

8.2.2.2. Target Disease Prevalence

8.2.2.3. Regulatory Framework

8.2.2.4. Reimbursement Framework

8.2.2.5. U.S. Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.2.3. Canada

8.2.3.1. Key Country Dynamics

8.2.3.2. Target Disease Prevalence

8.2.3.3. Regulatory Framework

8.2.3.4. Reimbursement Framework

8.2.3.5. Canada Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.2.4. Mexico

8.2.4.1. Key Country Dynamics

8.2.4.2. Target Disease Prevalence

8.2.4.3. Regulatory Framework

8.2.4.4. Reimbursement Framework

8.2.4.5. Mexico Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.3. Europe

8.3.1. Europe Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.3.2. UK

8.3.2.1. Key Country Dynamics

8.3.2.2. Target Disease Prevalence

8.3.2.3. Regulatory Framework

8.3.2.4. Reimbursement Framework

8.3.2.5. Uk Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.3.3. Germany

8.3.3.1. Key Country Dynamics

8.3.3.2. Target Disease Prevalence

8.3.3.3. Regulatory Framework

8.3.3.4. Reimbursement Framework

8.3.3.5. Germany Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.3.4. France

8.3.4.1. Key Country Dynamics



8.3.4.2. Target Disease Prevalence

8.3.4.3. Regulatory Framework

8.3.4.4. Reimbursement Framework

8.3.4.5. France Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

8.3.5. Italy

8.3.5.1. Key Country Dynamics

8.3.5.2. Target Disease Prevalence

8.3.5.3. Regulatory Framework

8.3.5.4. Reimbursement Framework

8.3.5.5. Italy Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD

Million)

8.3.6. Spain

8.3.6.1. Key Country Dynamics

8.3.6.2. Target Disease Prevalence

8.3.6.3. Regulatory Framework

8.3.6.4. Reimbursement Framework

8.3.6.5. Spain Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD

Million)

8.3.7. Denmark

8.3.7.1. Key Country Dynamics

8.3.7.2. Target Disease Prevalence

8.3.7.3. Regulatory Framework

8.3.7.4. Reimbursement Framework

8.3.7.5. Denmark Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

8.3.8. Sweden

8.3.8.1. Key Country Dynamics

8.3.8.2. Target Disease Prevalence

8.3.8.3. Regulatory Framework

8.3.8.4. Reimbursement Framework

8.3.8.5. Sweden Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

8.3.9. Norway

8.3.9.1. Key Country Dynamics

8.3.9.2. Target Disease Prevalence

8.3.9.3. Regulatory Framework

8.3.9.4. Reimbursement Framework

8.3.9.5. Norway Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030



(USD Million)

#### 8.4. Asia Pacific

##### 8.4.1. Asia Pacific Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.4.2. Japan

###### 8.4.2.1. Key Country Dynamics

###### 8.4.2.2. Target Disease Prevalence

###### 8.4.2.3. Regulatory Framework

###### 8.4.2.4. Reimbursement Framework

##### 8.4.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.4.3. China

###### 8.4.3.1. Key Country Dynamics

###### 8.4.3.2. Target Disease Prevalence

###### 8.4.3.3. Regulatory Framework

###### 8.4.3.4. Reimbursement Framework

##### 8.4.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.4.4. India

###### 8.4.4.1. Key Country Dynamics

###### 8.4.4.2. Target Disease Prevalence

###### 8.4.4.3. Regulatory Framework

###### 8.4.4.4. Reimbursement Framework

##### 8.4.4.5. India Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD

Million)

##### 8.4.5. Australia

###### 8.4.5.1. Key Country Dynamics

###### 8.4.5.2. Target Disease Prevalence

###### 8.4.5.3. Regulatory Framework

###### 8.4.5.4. Reimbursement Framework

##### 8.4.5.5. Australia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.4.6. South Korea

###### 8.4.6.1. Key Country Dynamics

###### 8.4.6.2. Target Disease Prevalence

###### 8.4.6.3. Regulatory Framework

###### 8.4.6.4. Reimbursement Framework

##### 8.4.6.5. South Korea Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

#### 8.4.7. Thailand

8.4.7.1. Key Country Dynamics

8.4.7.2. Target Disease Prevalence

8.4.7.3. Regulatory Framework

8.4.7.4. Reimbursement Framework

8.4.7.5. Thailand Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

#### 8.5. Latin America

8.5.1. Latin America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.5.2. Brazil

8.5.2.1. Key Country Dynamics

8.5.2.2. Target Disease Prevalence

8.5.2.3. Regulatory Framework

8.5.2.4. Reimbursement Framework

8.5.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

##### 8.5.3. Argentina

8.5.3.1. Key Country Dynamics

8.5.3.2. Target Disease Prevalence

8.5.3.3. Regulatory Framework

8.5.3.4. Reimbursement Framework

8.5.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030

(USD Million)

#### 8.6. Middle East and Africa

8.6.1. Middle East and Africa Dopamine Agonist Market Estimates and Forecasts, 2018 – 2030 (USD Million)

##### 8.6.2. South Africa

8.6.2.1. Key Country Dynamics

8.6.2.2. Target Disease Prevalence

8.6.2.3. Regulatory Framework

8.6.2.4. Reimbursement Framework

8.6.2.5. South Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

##### 8.6.3. Saudi Arabia

8.6.3.1. Key Country Dynamics

8.6.3.2. Target Disease Prevalence

8.6.3.3. Regulatory Framework

8.6.3.4. Reimbursement Framework

8.6.3.5. Saudi Arabia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.6.4. UAE

8.6.4.1. Key Country Dynamics

8.6.4.2. Target Disease Prevalence

8.6.4.3. Regulatory Framework

8.6.4.4. Reimbursement Framework

8.6.4.5. UAE Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

8.6.5. Kuwait

8.6.5.1. Key Country Dynamics

8.6.5.2. Target Disease Prevalence

8.6.5.3. Regulatory Framework

8.6.5.4. Reimbursement Framework

8.6.5.5. Kuwait Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

## **CHAPTER 9. COMPETITIVE LANDSCAPE**

9.1. Recent Developments & Impact Analysis by Key Market Participants

9.2. Company Categorization

9.3. Participant Overview

9.4. Financial Performance

9.5. Product Bench Marking

9.6. Company Market Share Analysis, 2024

9.7. Company Profiles

9.7.1. Teva Pharmaceutical Industries Ltd

9.7.1.1. Participant's Overview

9.7.1.2. Financial Performance

9.7.1.3. Product Benchmarking

9.7.1.4. Recent Developments/ Strategic Initiatives

9.7.2. GSK plc.

9.7.2.1. Participant's Overview

9.7.2.2. Financial Performance

9.7.2.3. Product Benchmarking

9.7.2.4. Recent Developments/ Strategic Initiatives

9.7.3. Supernus Pharmaceuticals, Inc.

9.7.3.1. Participant's Overview

9.7.3.2. Financial Performance

- 9.7.3.3. Product Benchmarking
- 9.7.3.4. Recent Developments/ Strategic Initiatives
- 9.7.4. H. Lundbeck A/S
  - 9.7.4.1. Participant's Overview
  - 9.7.4.2. Financial Performance
  - 9.7.4.3. Product Benchmarking
  - 9.7.4.4. Recent Developments/ Strategic Initiatives
- 9.7.5. Amneal Pharmaceuticals LLC
  - 9.7.5.1. Participant's Overview
  - 9.7.5.2. Financial Performance
  - 9.7.5.3. Product Benchmarking
  - 9.7.5.4. Recent Developments/ Strategic Initiatives
- 9.7.6. UCB Pharma
  - 9.7.6.1. Participant's Overview
  - 9.7.6.2. Financial Performance
  - 9.7.6.3. Product Benchmarking
  - 9.7.6.4. Recent Developments/ Strategic Initiatives
- 9.7.7. Novartis AG
  - 9.7.7.1. Participant's Overview
  - 9.7.7.2. Financial Performance
  - 9.7.7.3. Product Benchmarking
  - 9.7.7.4. Recent Developments/ Strategic Initiatives
- 9.7.8. VeroScience LLC.
  - 9.7.8.1. Participant's Overview
  - 9.7.8.2. Financial Performance
  - 9.7.8.3. Product Benchmarking
  - 9.7.8.4. Recent Developments/ Strategic Initiatives
- 9.7.9. Pfizer Inc.
  - 9.7.9.1. Participant's Overview
  - 9.7.9.2. Financial Performance
  - 9.7.9.3. Product Benchmarking
  - 9.7.9.4. Recent Developments/ Strategic Initiatives
- 9.7.10. Boehringer Ingelheim Pharmaceuticals, Inc.
  - 9.7.10.1. Participant's Overview
  - 9.7.10.2. Financial Performance
  - 9.7.10.3. Product Benchmarking
  - 9.7.10.4. Recent Developments/ Strategic Initiatives

## **CHAPTER 10. CONCLUSION**

## I would like to order

Product name: Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/D2A32AB30D30EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D2A32AB30D30EN.html>